Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden · Delayed Price · Currency is SEK | Market Cap | 226.66M -19.2% |
| Revenue (ttm) | 152.35M +2.9% |
| Net Income | 127.24M |
| EPS | 7.74 |
| Shares Out | 20.61M |
| PE Ratio | 1.78 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 169,112 |
| Average Volume | 82,212 |
| Open | 10.75 |
| Previous Close | 10.00 |
| Day's Range | 10.75 - 12.30 |
| 52-Week Range | 5.42 - 38.10 |
| Beta | 0.52 |
| RSI | 69.14 |
| Earnings Date | May 5, 2026 |
About Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease and axial s... [Read more]
Financial Performance
Financial StatementsNews
Xbrane Biopharma AB Earnings Call Transcript: Q4 2025
Ximluci saw strong year-over-year growth and profit contribution, but faces increased price pressure and competition in Europe. Cost reduction measures and FDA resubmission are key focuses, while Xdivane development remains on track for a 2027 US launch.
Xbrane Biopharma AB Earnings Call Transcript: Q3 2025
Ximluci maintained stable market share and revenue in Q3, with resumed shipments and a strong cash position following a directed share issue. FDA approval for U.S. launch is delayed, while Xdivane development progresses on track for a 2028 launch.
Xbrane Biopharma AB Transcript: Investing in Life Science 2025
Biosimilars are gaining market share due to regulatory changes and growing acceptance. Ximluci, a Lucentis biosimilar, is performing well in Europe and preparing for a U.S. launch, while Xdivane, an Opdivo biosimilar, targets a 2029 launch. Recent restructuring and partnerships have improved financial stability and global reach.
Xbrane Biopharma AB Earnings Call Transcript: Q2 2025
Ximluci saw 11% volume growth in Europe in Q2, with U.S. FDA approval for Lucumsi expected in October. Xtovane's clinical trial is underway, and the Alvotech deal improved liquidity and reduced debt. SEK 240 million was raised in a directed share issue.
Xbrane Biopharma AB Earnings Call Transcript: Q1 2025
Divestment of the XB003 program and R&D to Alvotech will strengthen the financial position, reduce costs, and allow focus on Ximluci and Xdivane. Q1 2025 saw strong Ximluci growth, with SEK 93.2 million revenue and 57% gross margin.
Xbrane Biopharma AB Earnings Call Transcript: Q4 2024
Q4 2024 saw strong revenue and margin growth, driven by Ximluci's European expansion and new licensing deals. Regulatory progress continues for U.S. approval, while out-licensing and milestone payments are key to future cash flow.
Xbrane Biopharma AB Earnings Call Transcript: Q3 2024
Q3 2024 saw SEK 67 million in revenue and a 45% gross margin, driven by Ximluci's strong volume growth in Europe and ongoing out-licensing negotiations for Xdivane and XB003. Cash position ended at SEK 31 million, with significant R&D and cost-saving measures in place.
Xbrane Biopharma AB Earnings Call Transcript: Q2 2024
Q2 2024 saw strong Ximluci sales growth and improved margins, with active out-licensing of pipeline assets to secure financial stability. Cost controls and regulatory progress support a positive outlook, but success depends on closing new partnerships by October 2024.